Thursday’s insider activity: Notable buys and strategic sales

Insider activity was mixed: Jewett Cameron Trading Co coordinated buys (~$25.9k at $2.35/share) and Hartree Partners bought 764,202 HUDSON TECHNOLOGIES shares (~$4.48M), while CoreWeave saw large insider selling (CEO/president sold ~$37.7M; stock down ~15% over the week and ~51% YTD). Several additional names showed buys near highs (e.g., Boundless Bio up 137% YoY), with multiple InvestingPro notes labeling some stocks undervalued and others overvalued.

Analysis

The highest-signal item here is not “insiders bought,” but who bought and how much follow-through capital they were willing to commit. When a strategic holder adds size in a small-cap with limited liquidity, it can tighten the float and create a squeeze dynamic for 1-3 months, especially if the underlying business has a policy-driven tailwind that the market is underpricing. By contrast, the broad set of sales in high-multiple names looks more like supply from people monetizing duration than a clean bearish call, so the near-term read is mostly on valuation and positioning, not on a sudden collapse in fundamentals.

HDSN is the cleanest relative-value long because the buyer is effectively signaling comfort with the medium-term earnings power while the stock still trades like a cyclical rather than a scarce asset. A strategic accumulation at scale can matter more than a standard insider buy: it can precede capital allocation changes, partnership interest, or simply reduced free float support. That creates an asymmetric setup versus names where insider selling is mechanically tied to taxes, RSUs, or 10b5-1 plans and thus has much weaker predictive power.

The contrarian point is that the market may be overreacting to the sell-side optics in CRWV/ALAB/HOOD while underreacting to the more informative buy-side signal in HDSN. The risk to the long-HDSN thesis is simple: if the next operating update shows no margin inflection or if the stock can’t hold recent support after the insider window closes, this becomes a transient sponsorship trade rather than a durable rerating. For the frothier AI and biotech momentum names, the reversal trigger is any slowdown in growth or a continued multiple reset; those can happen faster than fundamentals change, but the insider tape alone is not enough to time them precisely.

Key Decisions for Investors

• Long HDSN / short CRWV for 1-3 months: favor the name with credible strategic accumulation over the one where leverage and cash burn make the equity a residual claim; trim if HDSN loses post-buy support or CRWV announces faster-than-expected deleveraging.
• On CRWV, sell strength into any rebound rather than chase the decline: the cleaner trade is a call spread or outright short on rallies toward prior tape highs, with risk defined by evidence of FCF inflection or debt term-out.
• Avoid paying up for ALAB after the run: insider selling here is not a stand-alone short signal, but it is a reason to use rallies to hedge exposure via put spreads or to wait for a lower entry after the next growth-print catalyst.
• Treat COLB and JCTC as no-action names unless liquidity or earnings data improves; the insider buys are too small or too mechanical to justify fresh capital at current levels.
• Watch HDSN into the next quarterly update: if revenue/margin commentary confirms pricing power, add on pullbacks; if not, treat the insider bid as temporary sponsorship and exit.